Revvity Inc (RVTY) Stock Forecast & Price Target

Revvity is well positioned because its Life Sciences business is a pure-play on pre-clinical R&D, where improving biotech funding, recovering pharma spending, and early AI-driven screening demand are already translating into multiple system orders per customer and high incremental margins on reagents and antibodies. Its diagnostics portfolio adds durable, high-quality growth through EUROIMMUN’s global autoimmune leadership and the newborn screening franchise, which screens tens of millions of babies annually across >100 countries and benefits from high switching costs plus sticky contracts like Genomics England. The Signals software platform further strengthens the case, with 47 of the top 50 pharma and biotech customers, ~1/3 SaaS conversion, and AI-enabled products such as Xynthetica, BioDesign, and LabGistics supporting higher-margin, more scalable growth.

Revvity is viewed negatively because its core businesses are not yet delivering the growth needed to justify the company’s long-term framework: organic growth is running below the 6-8% target, with estimates of 4.9% in FY26 and 5.1% in FY27, while adjusted operating margin is still only modeled at 28.7% and 29.2% versus mid-30% goals. In addition, the high-quality earnings story is being challenged by softer momentum in Euroimmun, barely positive growth in the BioLegend-anchored reagents business, and a Reproductive Health segment that is exposed to declining birth rates and tougher comparisons as the Genomics England contract annualizes in Q4 ’26. The China divestiture may remove a drag, but it also underscores persistent regional weakness, policy pressure, and the risk that the company’s premium mix and recurring revenue profile are not translating into the accelerated execution investors need.